hormone-refractory prostate adenocarcinoma
Showing 1 - 25 of >10,000
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide
Not yet recruiting
- Prostate Adenocarcinoma
- +2 more
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
- Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 4, 2023
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 Trial in Houston (drug,
Completed
- Prostate Adenocarcinoma
- +4 more
- Abiraterone Acetate
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial
Active, not recruiting
- Hormone-Resistant Prostate Cancer
- +6 more
- Pembrolizumab
- pTVG-HP Plasmid DNA Vaccine
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Nov 8, 2022
Refractory Cancer Trial in Hamburg (BIBW 2992 (Afatinib))
Terminated
- Refractory Cancer
- BIBW 2992 (Afatinib)
-
Hamburg, GermanyUniversity Medical Center Hamburg-Eppendorf
Jun 29, 2022
Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer Trial in United
Active, not recruiting
- Prostate Carcinoma Metastatic to the Bone
- +2 more
- Niraparib
- Radium Ra 223 Dichloride
-
Birmingham, Alabama
- +5 more
Feb 10, 2021
Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)
Recruiting
- Metastatic Hormone Refractory Prostate Cancer
- Cabozantinib
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Jun 6, 2022
Prostate Cancer, Prostate Adenocarcinoma Trial in Charlotte (ADT+Docetaxel+Enzalutamide)
Active, not recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
-
Charlotte, North CarolinaLevine Cancer Institute
Jan 12, 2023
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy Trial in France (Abiraterone)
Completed
- Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
-
Bordeaux, France
- +4 more
May 18, 2022
Prostate Adenocarcinoma Trial in Duarte (drug, radiation, other)
Recruiting
- Prostate Adenocarcinoma
- Leuprolide Acetate
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Sep 14, 2022
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone Trial in Houston (Abiraterone
Active, not recruiting
- Metastatic Prostate Carcinoma
- +5 more
- Abiraterone Acetate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 26, 2022
Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Seattle
Active, not recruiting
- Castration-Sensitive Prostate Carcinoma
- +7 more
- Antiandrogen Therapy
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 8, 2022
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7 Trial in Duarte, South Pasadena (drug, radiation, other)
Active, not recruiting
- PSA Level Greater Than Two
- Stage IV Prostate Adenocarcinoma AJCC v7
- Bicalutamide
- +4 more
-
Duarte, California
- +1 more
Apr 4, 2022
Metastatic Malignant Tumor in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7 Trial in
Active, not recruiting
- Metastatic Malignant Neoplasm in Lymph Node
- +3 more
- Antiandrogen Therapy
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Mar 3, 2022
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,
Not yet recruiting
- Androgen-Independent Prostatic Cancer
- +8 more
- lorigerlimab
- +2 more
- (no location specified)
May 4, 2023
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial in Philadelphia
Recruiting
- Prostate Adenocarcinoma
- +2 more
- MRI-guided Intensity-Modulated Radiation Therapy
- +7 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 4, 2023
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,
Active, not recruiting
- Castration-Resistant Prostate Carcinoma
- +4 more
- Enzalutamide
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 26, 2022
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 Trial in Los Angeles (drug,
Not yet recruiting
- Prostate Adenocarcinoma
- +3 more
- Apalutamide
- +7 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 5, 2023
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Stage IV Prostate Adenocarcinoma AJCC v7 Trial in Worldwide (drug, other, procedure)
Recruiting
- Stage IV Prostate Adenocarcinoma AJCC v7
- Antiandrogen Therapy
- +5 more
-
Duarte, California
- +15 more
Jan 24, 2023
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Trial in Baltimore (Ipilimumab, Nivolumab,
Completed
- Prostate Cancer
- +2 more
- Ipilimumab
- +2 more
-
Baltimore, MarylandJohns Hopkins University/Sidney Kimmel Cancer Center
Jan 6, 2022
Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma Trial in United States (Sacituzumab Govitecan-hziy (SG))
Completed
- Gastric Adenocarcinoma
- +15 more
- Sacituzumab Govitecan-hziy (SG)
-
Aurora, Colorado
- +11 more
Aug 10, 2021
Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Active, not recruiting
- Hormone-Resistant Prostate Cancer
- +3 more
- Laboratory Biomarker Analysis
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022